Skip to main content

Table 4 Relationship between immunochemical features and tumor stage

From: Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature

Target expression

Ta

Tis (CIS)

T1

T2

>T3, N+ or M+

p-value

Target expression

Ta

Tis (CIS)

T1

T2

>T3, N+ or M+

p-value

VEGFA

      

APOE

      

1

10 (25.0%)

5 (29.4%)

18 (33.3%)

6 (25.0%)

8 (28.6%)

0.670

1

13 (27.7%)

1 (6.3%)

9 (15.3%)

7 (24.1%)

0 (0%)

0.009

2

6 (15.0%)

5 (29.4%)

17 (31.5%)

6 (25.0%)

9 (32.1%)

 

2

14 (29.8%)

6 (37.5%)

14 (23.7%)

5 (17.2%)

5 (13.9%)

 

3

10 (25.0%)

4 (23.5%)

9 (16.7%)

7 (29.2%)

7 (25.0%)

 

3

10 (21.3%)

5 (31.3%)

13 (22.0%)

6 (20.7%)

17 (47.2%)

 

4

14 (35.0%)

3 (17.6%)

10 (18.5%)

5 (20.8%)

4 (14.3%)

 

4

10 (21.3%)

4 (25.0%)

23 (39.0%)

11 (37.9%)

14 (38.9%)

 

MMP9

      

SERPINA1

      

1

5 (11.6%)

 

4 (7.1%)

4 (13.8%)

 

0.036

1

11 (25.0%)

2 (13.3%)

16 (27.6%)

3 (10.7%)

2 (5.9%)

0.036

2

15 (34.9%)

5 (35.7%)

16 (28.6%)

4 (13.8%)

5 (14.3%)

 

2

10 (22.7%)

2 (13.3%)

12 (20.7%)

9 (32.1%)

4 (11.8%)

 

3

13 (30.2%)

5 (35.7%)

22 (39.3%)

7 (24.1%)

11 (31.4%)

 

3

10 (22.7%)

4 (26.7%)

19 (32.8%)

6 (21.4%)

9 (26.5%)

 

4

10 (23.3%)

4 (28.6%)

14 (25.0%)

14 (48.3%)

19 (54.3%)

 

4

13 (29.5%)

7 (46.7%)

11 (19.0%)

10 (35.7%)

19 (55.9%)

 

MMP10

      

SDC1

      

1

11 (25.6%)

8 (57.1%)

12 (21.8%)

2 (6.9%)

3 (8.3%)

0.036

1

6 (14.3%)

4 (21.1%)

5 (8.5%)

5 (17.2%)

7 (20.0%)

0.021

2

9 (20.9%)

2 (14.3%)

10 (18.2%)

8 (27.6%)

6 (16.7%)

 

2

9 (21.4%)

6 (31.6%)

5 (8.5%)

8 (27.6%)

6 (17.1%)

 

3

10 (23.3%)

3 (21.4%)

12 (21.8%)

9 (31.0%)

11 (30.6%)

 

3

13 (31.0%)

6 (31.6%)

17 (28.8%)

8 (27.6%)

16 (45.7%)

 

4

13 (30.2%)

1 (7.1%)

21 (38.2%)

10 (34.5%)

16 (44.4%)

 

4

14 (33.3%)

3 (15.8%)

32 (54.2%)

8 (27.6%)

6 (17.1%)

 

SERPINE1

      

ANG

      

1

19 (45.2%)

8 (53.3%)

12 (21.4%)

2 (7.1%)

3 (8.6%)

0.0003

1

0 (0%)

1 (5.9%)

0 (0%)

3 (10.3%)

0 (0%)

<0.0001

2

7 (16.7%)

1 (6.7%)

11 (19.6%)

4 (14.3%)

8 (22.9%)

 

2

23 (50.0%)

8 (47.1%)

16 (27.1%)

6 (20.7%)

1 (2.8%)

 

3

9 (21.4%)

5 (33.3%)

15 (26.8%)

5 (17.9%)

9 (25.7%)

 

3

12 (26.1%)

2 (11.8%)

24 (40.7%)

10 (34.5%)

15 (41.7%)

 

4

7 (16.7%)

1 (6.7%)

18 (32.1%)

17 (60.7%)

15 (42.9%)

 

4

11 (23.9%)

6 (35.3%)

19 (32.2%)

10 (34.5%)

20 (55.6%)

 

IL8

             

1

19 (41.3%)

7 (43.8%)

20 (33.3%)

4 (13.8%)

2 (5.4%)

0.001

       

2

12 (26.1%)

3 (18.8%)

16 (26.7%)

4 (13.8%)

6 (16.2%)

        

3

6 (13.0%)

1 (6.3%)

11 (18.3%)

10 (34.5%)

8 (21.6%)

        

4

9 (19.6%)

5 (31.3%)

13 (21.7%)

11 (37.9%)

21 (56.8%)

        

CA9

             

1

12 (26.7%)

4 (23.5%)

10 (16.7%)

7 (24.1%)

2 (5.3%)

0.308

       

2

12 (26.7%)

5 (29.4%)

9 (15.0%)

6 (20.7%)

14 (36.8%)

        

3

9 (20.0%)

3 (17.6%)

17 (28.3%)

6 (20.7%)

10 (26.3%)

        

4

12 (26.7%)

5 (29.4%)

24 (40.0%)

10 (34.5%)

12 (31.6%)